Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
复制标题
DOI：
10.1111/j.1463-1326.2007.00713.x
复制
发表时间：
2007-05-01
影响因子：
5.8
通讯作者：
Vaag, A.
中科院分区：
文献类型：
--
作者：
Lund, S. S.;Tarnow, L.;Vaag, A.
目的：二甲双胍因其降血糖和心血管保护潜力而成为肥胖 2 型糖尿病 (T2DM) 患者的“首选药物”。在非肥胖 T2DM 患者中，根据经验，胰岛素促分泌剂是首选。在这项由研究者发起的试验中，我们评估了二甲双胍与胰岛素促分泌剂瑞格列奈对非肥胖 T2DM 患者的血糖调节以及炎症标志物和胰岛素敏感性的影响。方法：一项为期 2 x 4 个月的单中心、双盲、双模拟交叉研究，涉及 96 名非肥胖（体重指数）患者
Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM.Methods: A single-centre, double-masked, double-dummy, crossover study during 2 x 4 months involved 96 non-obese (body mass index